僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b （a FGF receptor）. Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research